LEADER 03559nam  22005295  450 
001 9910437857503321
005 20251117071237.0
010   $a1-4614-8051-5
024 7 $a10.1007/978-1-4614-8051-8
035   $a(CKB)3710000000019038
035   $a(EBL)1466843
035   $a(SSID)ssj0001004882
035   $a(PQKBManifestationID)11642481
035   $a(PQKBTitleCode)TC0001004882
035   $a(PQKBWorkID)11051897
035   $a(PQKB)10859215
035   $a(DE-He213)978-1-4614-8051-8
035   $a(MiAaPQ)EBC1466843
035   $a(PPN)172420539
035   $a(EXLCZ)993710000000019038
100   $a20130906d2013      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAdvances in Chronic Lymphocytic Leukemia /$fedited by Sami Malek
205   $a1st ed. 2013.
210  1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2013.
215   $a1 online resource (337 p.)
225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v792
300   $aDescription based upon print version of record.
311 08$a1-4614-8050-7 
320   $aIncludes bibliographic references and index.
327   $aPreface -- B-cell receptor and antigens in CLL -- The CLL cell microenvironment -- Acquired genomic copy number aberrations in CLL -- Recurrent gene mutations in CLL -- TP53 aberrations in CLL -- Gene expression and epigenetic deregulation -- Apoptosis deregulation in CLL -- Richter?s Syndrome -- Molecular biomarkers in chronic lymphocytic leukemia -- Critical Signal Transduction Pathways in CLL -- Immunotherapies in CLL -- Novel therapeutic agents in CLL -- Inherited susceptibility to CLL -- miR deregulations in CLL -- Index.
330   $aChronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course.  While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatment of CLL are rooted in an in-depth understanding of the basic and translational biology of CLL.  In this book, CLL experts have contributed state-of-the-art summaries of various important aspects of CLL biology and have discussed the translational implication of such findings.  This book, which is directed at physicians and researchers alike, aims to educate broadly and deeply.  Intentionally, the many aspects and nuances of CLL clinical care that can only really be appreciated through direct patient care are not covered here, but instead, the book presents basic aspects of CLL that underlie many of the contemporary decisions that are made in CLL research and clinical settings. We hope that this book will critically inform the community and stimulate interest in CLL, which will ultimately translate into better CLL research, prognostication and therapy, with the end goal of providing a better outlook for patients afflicted with this common leukemia. .
410  0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v792
606   $aCancer$xResearch
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aCancer$xResearch.
615 14$aCancer Research.
676   $a610
702   $aMalek$b Sami$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910437857503321
996   $aAdvances in Chronic Lymphocytic Leukemia$92542169
997   $aUNINA